Private Equity's Big Guns Are Tearing Up the Rules on Leverage

As one of the world’s largest sovereign wealth funds warned this week that private equity is “very troubled” right now, a spate of recent buyout deals in Europe and the US points to a possible route out of the mire: The deep shift in how much debt this industry uses to fund its takeovers.

KKR & Co. has been busily dealmaking despite the gloom around President Donald Trump’s tariff upheavals, snapping up a couple of Swedish health specialists in the process. Fellow private equity firm Thoma Bravo, meanwhile, has pulled together one of the year’s biggest buyouts with the $10.6 billion purchase of Boeing Co.’s Jeppesen navigation unit and other assets.

Like KKR’s offers for Karo Healthcare and life sciences company Biotage AB, the Jeppesen deal shows how private equity is targeting higher-quality assets as it looks to put investors’ money to profitable use. But they’ve something else in common, too: Buyers are stumping up most of the finance themselves, with debt taking up a smaller share than was once the norm.

For a private equity industry that’s often pilloried for piling debt onto the companies it buys — or leveraging them up, in finance speak — this is part of a big shift. Back in the not-so-distant heyday of PE, it wasn’t unheard of for buyouts to include 70% of borrowed funding. Even 80% was doable when money was dirt cheap and firms took full advantage to juice their returns.

Since the turn of the decade, and as interest rates have spiked, the proportion of debt on many buyouts has reduced to more digestible levels as cash got more expensive. In recent weeks, a swath of deals shows how far the pendulum is swinging, with equity outweighing borrowed money in multiple cases.

The Biotage deal includes a slug of debt that’s worth only 20% or so of the 11.6 billion kronor ($1.2 billion) deal value, according to a person with knowledge of the matter. The Karo purchase involves a much bigger €1.1 billion ($1.25 billion) chunk of borrowing, but that’s less than the equity check. Elsewhere in Europe, Cinven agreed to buy nutrition specialist Nutrisens, with just a third of it expected to be debt funded, a person familiar said.

Spokespeople for KKR and Cinven declined to comment.